Evidence map›Paper›PMID 42049920›Full record

ReviewCancer chemotherapy and pharmacology2026

Deciphering autophagy-metabolism interactions in cancer drug resistance: a comprehensive review.

Mohanprasanth Aruchamy, Snega Ramanathan, Nandhini Shanmugam, Saravanan Muthupandian

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cancer chemotherapy and pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mohanprasanth AruchamyApplied NanoBio Therapeutics Laboratory, Department of Periodontics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, 600077, Tamil Nadu, India. mohanbiochemist03@gmail.com.ORCID http://orcid.org/0000-0001-9008-0814
Snega RamanathanAMR and Nanotherapeutic Lab, Department of Pharmacology, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Science (SIMATS), Chennai, Tamil Nadu, India.
Nandhini ShanmugamDepartment of Biochemistry, AMC College of Pharmacy, The Tamil Nadu Dr M.G.R Medical University, Karumathamapatti, Coimbatore, 641659, Tamil Nadu, India.
Saravanan MuthupandianAMR and Nanotherapeutic Lab, Department of Pharmacology, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Science (SIMATS), Chennai, Tamil Nadu, India.

Funding

Indian Council of Medical Research (2022-18903)
6 · The paper itself

Abstract

Drug resistance is a formidable obstacle in the treatment of various cancers, significantly undermining the efficacy of therapeutic interventions and posing a substantial challenge to achieving optimal clinical outcomes. Emerging research has highlighted the critical role of the interplay between autophagy and cellular metabolism in driving drug resistance. Autophagy, a cellular recycling process, and metabolic reprogramming, which involves alterations in cellular metabolic pathways, collectively enable cancer cells to survive and proliferate despite therapeutic stress. This comprehensive review aims to elucidate the mechanisms by which autophagy and metabolism interact to confer drug resistance in cancer cells. We explore how autophagy supports cancer cell survival by recycling nutrients and maintaining cellular homeostasis under stress. Furthermore, we discuss about metabolic reprogramming, specifically enhanced glycolysis, oxidative phosphorylation, and fatty acid metabolism, and how these metabolic shifts contribute to the development of drug resistance.

Indexed as

Antineoplastic AgentsAutophagyDrug Resistance, NeoplasmNeoplasmsAnimalsHumansMetabolic ReprogrammingAntineoplastic AgentsAutophagyCancer progressionDrug resistanceInhibitorMetabolisms

Identifiers

PMID42049920

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.